Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Luke, Jason J.
Gajewski, Thomas F.
Funding for this research was provided by:
Melanoma Research Alliance
Harry J. Lloyd Charitable Trust
National Institutes of Health (1K12CA139160-05)